258503-86-5Relevant articles and documents
PYRIMIDINE DERIVATIVES
-
Page 30, (2010/02/10)
The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; Ris hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Qis aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
Cumming, John G.,McKenzie, Caroline L.,Bowden, Stuart G.,Campbell, Douglas,Masters, David J.,Breed, Jason,Jewsbury, Philip J.
, p. 5389 - 5394 (2007/10/03)
SAR studies led to the identification of 4-(3-benzoylamino-6-methyl- anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo. SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo.
PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS
-
Page/Page column 92, (2008/06/13)
-